Poly(ADP-Ribose) polymerases new players in the pathogenesis of exocrine pancreatic diseases

American Journal of Pathology

Volumn 186, Issue 2, 2016, Pages 234-241

  Martínez Bosch, Neus ^a   Fernández Zapico, Martin E ^b   Navarro, Pilar ^a   Yélamos, José ^a,c  

^a HOSPITAL DEL MAR   (Spain)

^b MAYO CLINIC   (United States)

^c CIBERER (Center for Biomedical Research on Rare Diseases) U714   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ANIMAL; CELL DEATH; DNA DAMAGE; DRUG EFFECTS; HUMAN; METABOLISM; NEOPLASMS; PANCREATIC DISEASES;

ANIMALS; CELL DEATH; DNA DAMAGE; HUMANS; NEOPLASMS; PANCREATIC DISEASES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84955308982     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2015.09.021     Document Type: Review

References (50)

1. S. Tangutoori, P. Baldwin, and S. Sridhar PARP inhibitors: a new era of targeted therapy Maturitas 81 2015 5 9
2. J. Yelamos, J. Farres, L. Llacuna, C. Ampurdanes, and J. Martin-Caballero PARP-1 and PARP-2: new players in tumour development Am J Cancer Res 1 2011 328 346
3. J. Michels, F. Obrist, M. Castedo, I. Vitale, and G. Kroemer PARP and other prospective targets for poisoning cancer cell metabolism Biochem Pharmacol 92 2014 164 171
4. M.J. Menissier de, M. Ricoul, L. Tartier, C. Niedergang, A. Huber, F. Dantzer, V. Schreiber, J.C. Ame, A. Dierich, M. LeMeur, L. Sabatier, P. Chambon, and G. de Murcia Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse EMBO J 22 2003 2255 2263
5. Z.Q. Wang, B. Auer, L. Stingl, H. Berghammer, D. Haidacher, M. Schweiger, and E.F. Wagner Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease Genes Dev 9 1995 509 520
6. J.M. de Murcia, C. Niedergang, C. Trucco, M. Ricoul, B. Dutrillaux, M. Mark, F.J. Oliver, M. Masson, A. Dierich, M. LeMeur, C. Walztinger, P. Chambon, and G. de Murcia Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells Proc Natl Acad Sci U S A 94 1997 7303 7307
7. B.A. Gibson, and W.L. Kraus New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs Nat Rev Mol Cell Biol 13 2012 411 424
8. R. Valdor, V. Schreiber, L. Saenz, T. Martinez, A. Munoz-Suano, M. Dominguez-Villar, P. Ramirez, P. Parrilla, E. Aguado, F. Garcia-Cozar, and J. Yelamos Regulation of NFAT by poly(ADP-ribose) polymerase activity in T cells Mol Immunol 45 2008 1863 1871
9. M.I. Rodriguez, A. Peralta-Leal, F. O'Valle, J.M. Rodriguez-Vargas, A. Gonzalez-Flores, J. Majuelos-Melguizo, L. Lopez, S. Serrano, A.G. de Herreros, J.C. Rodriguez-Manzaneque, R. Fernandez, R.G. Del Moral, J.M. de Almodovar, and F.J. Oliver PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation PLoS Genet 9 2013 e1003531
10. A. Pyriochou, G. Olah, E.A. Deitch, C. Szabo, and A. Papapetropoulos Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34 Int J Mol Med 22 2008 113 118
11. F. Aredia, and A.I. Scovassi Poly(ADP-ribose): a signaling molecule in different paradigms of cell death Biochem Pharmacol 92 2014 157 163
12. P.G. Lankisch, M. Apte, and P.A. Banks Acute pancreatitis Lancet 386 2015 85 96
13. H.L. Pahl Activators and target genes of Rel/NF-kappaB transcription factors Oncogene 18 1999 6853 6866
14. T.L. Andreone, M. O'Connor, A. Denenberg, P.W. Hake, and B. Zingarelli Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts J Immunol 170 2003 2113 2120
15. R.A. Mota, F. Sanchez-Bueno, L. Saenz, D. Hernandez-Espinosa, J. Jimeno, P.L. Tornel, A. Martinez-Torrano, P. Ramirez, P. Parrilla, and J. Yelamos Inhibition of poly(ADP-ribose) polymerase attenuates the severity of acute pancreatitis and associated lung injury Lab Invest 85 2005 1250 1262
16. E. Mazzon, T. Genovese, P.R. Di, C. Muia, C. Crisafulli, G. Malleo, E. Esposito, R. Meli, E. Sessa, and S. Cuzzocrea Effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, in a mouse model of acute pancreatitis induced by cerulein Eur J Pharmacol 549 2006 149 156
17. R. Mota, F. Sanchez-Bueno, J.J. Berenguer-Pina, D. Hernandez-Espinosa, P. Parrilla, and J. Yelamos Therapeutic treatment with poly(ADP-ribose) polymerase inhibitors attenuates the severity of acute pancreatitis and associated liver and lung injury Br J Pharmacol 151 2007 998 1005
18. J. Yu, W. Deng, W. Wang, Y. Ding, H. Jin, C. Chen, X. Chen, X. Xiong, and S. Xu Inhibition of poly(ADP-ribose) polymerase attenuates acute kidney injury in sodium taurocholate-induced acute pancreatitis in rats Pancreas 41 2012 1299 1305
19. I. Garrido-Laguna, and M. Hidalgo Pancreatic cancer: from state-of-the-art treatments to promising novel therapies Nat Rev Clin Oncol 12 2015 319 334
20. J. Bendell, E.M. O'Reilly, M.R. Middleton, I. Chau, H. Hochster, A. Fielding, W. Burke, and H. Burris III Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer Ann Oncol 26 2015 804 811
21. H.J. Kindler, G.Y. Locker, H. Mann, and T. Golan POLO: a randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2mutation (gBRCAm) who have not progressed following first-line chemotherapy J Clin Oncol 33 2015 abstr TPS4149
22. F. Rojo, J. Garcia-Parra, S. Zazo, I. Tusquets, J. Ferrer-Lozano, S. Menendez, P. Eroles, C. Chamizo, S. Servitja, N. Ramirez-Merino, F. Lobo, B. Bellosillo, J.M. Corominas, J. Yelamos, S. Serrano, A. Lluch, A. Rovira, and J. Albanell Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer Ann Oncol 23 2012 1156 1164
23. A. Ashworth A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair J Clin Oncol 26 2008 3785 3790
24. F. Klauschen, M. von Winterfeld, A. Stenzinger, B.V. Sinn, J. Budczies, C. Kamphues, M. Bahra, D. Wittschieber, W. Weichert, J. Striefler, H. Riess, M. Dietel, and C. Denkert High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer Histopathology 61 2012 409 416
25. N. Martinez-Bosch, M. Iglesias, J. Munne-Collado, C. Martinez-Caceres, M. Moreno, C. Guerra, J. Yelamos, and P. Navarro Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer J Pathol 234 2014 214 227
26. M.A. Lowery, F. Vanoli, K.H. Yu, M. Jasin, E.M. O'Reilly, and M.E. Moynahan Inhibition of poly (ADP-ribose) polymerase-1 (PARP-1) to increase radiosensitivity of human pancreatic cancer (PAC) cell lines proficient in homology-directed repair (HDR) J Clin Oncol 30 Suppl 4 2012 abstract 204
27. J.A. De Soto, and R. Mullins The use of PARP inhibitors as single agents and as chemosensitizers in sporadic pancreatic cancer J Clin Oncol 29 2011 e13542
28. D. Karnak, C.G. Engelke, L.A. Parsels, T. Kausar, D. Wei, J.R. Robertson, K.B. Marsh, M.A. Davis, L. Zhao, J. Maybaum, T.S. Lawrence, and M.A. Morgan Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer Clin Cancer Res 20 2014 5085 5096
29. M.A. Lowery, A. Lee, E. Tobias, P. Sung, U. Bhanot, R. Shakya, T. Ludwig, E.M. O'Reilly, M. Jasin, and M.E. Moynahan Evaluation of PARP inhibition as a platinum sparing strategy in Brca2-deficient pancreatic tumors J Clin Oncol 32 2014 e15237
30. D.R. Fogelman, R.A. Wolff, S. Kopetz, M. Javle, C. Bradley, I. Mok, F. Cabanillas, and J.L. Abbruzzese Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer Anticancer Res 31 2011 1417 1420
31. K. Leung, and M.W. Saif BRCA-associated pancreatic cancer: the evolving management JOP 14 2013 149 151
32. B. Kaufman, R. Shapira-Frommer, R.K. Schmutzler, M.W. Audeh, M. Friedlander, J. Balmana, G. Mitchell, G. Fried, S.M. Stemmer, A. Hubert, O. Rosengarten, M. Steiner, N. Loman, K. Bowen, A. Fielding, and S.M. Domchek Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation J Clin Oncol 33 2015 244 250
33. E.M. O'Reilly, M.A. Lowery, M.F. Segal, S.C. Smith, M.J. Moore, H.L. Kindler, T. Golan, A. Segal, E.E. Salo-Mullen, E. Hollywood, A.S. Epstein, M. Capanu, M.E. Moynahan, A. Fusco, Z.K. Stadler, R.K. Gian-Do, A.P. Chen, K.H. Yu, L.H. Tang, and D.P. Kelsen Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC) J Clin Oncol 32 2014 abstr4023
34. M.C. Villarroel, N.V. Rajeshkumar, I. Garrido-Laguna, A. De Jesus-Acosta, S. Jones, A. Maitra, R.H. Hruban, J.R. Eshleman, A. Klein, D. Laheru, R. Donehower, and M. Hidalgo Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer Mol Cancer Ther 10 2011 3 8
35. A. Bhalla, and M.W. Saif PARP-inhibitors in BRCA-associated pancreatic cancer JOP 15 2014 340 343
36. S. Holter, A. Borgida, A. Dodd, R. Grant, K. Semotiuk, D. Hedley, N. Dhani, S. Narod, M. Akbari, M. Moore, and S. Gallinger Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma J Clin Oncol 33 2015 3124 3129
37. D.B. Zhen, K.G. Rabe, S. Gallinger, S. Syngal, A.G. Schwartz, M.G. Goggins, R.H. Hruban, M.L. Cote, R.R. McWilliams, N.J. Roberts, L.A. Cannon-Albright, D. Li, K. Moyes, R.J. Wenstrup, A.R. Hartman, D. Seminara, A.P. Klein, and G.M. Petersen BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study Genet Med 17 2015 569 577
38. N. Waddell, M. Pajic, A.M. Patch, D.K. Chang, K.S. Kassahn, P. Bailey, and et al. Whole genomes redefine the mutational landscape of pancreatic cancer Nature 518 2015 495 501
39. A.M. Mendes-Pereira, S.A. Martin, R. Brough, A. McCarthy, J.R. Taylor, J.S. Kim, T. Waldman, C.J. Lord, and A. Ashworth Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors EMBO Mol Med 1 2009 315 322
40. V.J. Weston, C.E. Oldreive, A. Skowronska, D.G. Oscier, G. Pratt, M.J. Dyer, G. Smith, J.E. Powell, Z. Rudzki, P. Kearns, P.A. Moss, A.M. Taylor, and T. Stankovic The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo Blood 116 2010 4578 4587
41. J. Rios, and S. Puhalla PARP inhibitors in breast cancer: BRCA and beyond Oncology (Williston Park) 25 2011 1014 1025
42. E.P. Sandgren, C.J. Quaife, A.G. Paulovich, R.D. Palmiter, and R.L. Brinster Pancreatic tumor pathogenesis reflects the causative genetic lesion Proc Natl Acad Sci U S A 88 1991 93 97
43. A. Maitra, and R.H. Hruban Pancreatic cancer Annu Rev Pathol 3 2008 157 188
44. C. To, E.H. Kim, D.B. Royce, C.R. Williams, R.M. Collins, R. Risingsong, M.B. Sporn, and K.T. Liby The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice Cancer Prev Res (Phila) 7 2014 698 707
45. S.N. Chand, F.F. Blanco, M. Jimbo, T.N. Tsangaris, M. Cristofanilli, C.J. Yeo, J.M. Winter, M.J. Pishvaian, and J.R. Brody PARP inhibitors for chemoprevention: letter Cancer Prev Res (Phila) 7 2014 1170 1171
46. S.F. Garcia, L. Virag, P. Jagtap, E. Szabo, J.G. Mabley, L. Liaudet, A. Marton, D.G. Hoyt, K.G. Murthy, A.L. Salzman, G.J. Southan, and C. Szabo Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation Nat Med 7 2001 108 113
47. M. Li, and X. Yu The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy Oncogene 34 2014 3349 3356
48. A.A. Antolin, X. Jalencas, J. Yelamos, and J. Mestres Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology ACS Chem Biol 7 2012 1962 1967
49. E. Wahlberg, T. Karlberg, E. Kouznetsova, N. Markova, A. Macchiarulo, A.G. Thorsell, E. Pol, A. Frostell, T. Ekblad, D. Oncu, B. Kull, G.M. Robertson, R. Pellicciari, H. Schuler, and J. Weigelt Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors Nat Biotechnol 30 2012 283 288
50. J.D. Steffen, J.R. Brody, R.S. Armen, and J.M. Pascal Structural implications for selective targeting of PARPs Front Oncol 3 2013 301